Poor outcome for children and adolescents with progressive disease or relapse of lymphoblastic lymphoma: a report from the berlin-frankfurt-muenster group.
about
Targeted Therapies for the Treatment of Pediatric Non-Hodgkin Lymphomas: Present and FutureNon-Hodgkin Lymphoma in Children and Adolescents: Progress Through Effective Collaboration, Current Knowledge, and Challenges AheadThe immunophenotype of T-lymphoblastic lymphoma in children and adolescents: a Children's Oncology Group report.T-cell lymphoblastic lymphoma presenting with pleural effusion: A case report.High-risk pediatric acute lymphoblastic leukemia: to transplant or not to transplant?Autologous peripheral blood stem cell transplantation in children with refractory or relapsed lymphoma: results of Children's Oncology Group study A5962.Outcomes of dose-adjusted Berlin-Frankfurt-Münster-90 regimen without radiotherapy in adolescents and adults with T cell lymphoblastic lymphoma.NK/T-cell lymphomas in childrenLymphoblastic lymphoma in childhood and adolescence.Effective childhood cancer treatment: the impact of large scale clinical trials in Germany and Austria.XI. How to treat children and adolescents with relapsed non-Hodgkin lymphoma?Biomarkers in childhood non-Hodgkin's lymphomas.Management of Non-Hodgkin Lymphoma: ICMR Consensus Document.Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015.Constitutional mismatch repair deficiency syndrome: clinical description in a French cohort.Safety and efficacy of nelarabine in children and young adults with relapsed or refractory T-lineage acute lymphoblastic leukaemia or T-lineage lymphoblastic lymphoma: results of a phase 4 study.Lymphoblastic lymphoma: an updated review on biology, diagnosis, and treatment.Molecular genetics of childhood, adolescent and young adult non-Hodgkin lymphoma.Current status and future directions of T-lymphoblastic lymphoma in children and adolescents.Childhood, adolescent and young adult non-Hodgkin lymphoma: state of the science.Over-expressed Fas improves the apoptosis of malignant T-cells in vitro and vivo.Relapsed or Refractory Lymphoblastic Lymphoma in Children: Results and Analysis of 23 Patients in the EORTC 58951 and the LMT96 Protocols.Detection and role of minimal disseminated disease in children with lymphoblastic lymphoma: The AIEOP experience.Outcome of children and adolescents with lymphoblastic lymphoma.Pediatric T- and NK-cell lymphomas: new biologic insights and treatment strategies.Mobilization and collection of CD34(+) cells for autologous transplantation of peripheral blood hematopoietic progenitor cells in children: analysis of two different granulocyte-colony stimulating factor doses.Should children with non-Hodgkin lymphoma be treated with different protocols according to histopathologic subtype?Disseminated lymphoblastic lymphoma in children and adolescents: results of the COG A5971 trial: a report from the Children's Oncology Group.High levels of bcl-2 protein expression do not correlate with genetic abnormalities but predict worse prognosis in patients with lymphoblastic lymphoma.Absence of terminal deoxynucleotidyl transferase expression identifies a subset of high-risk adult T-lymphoblastic leukemia/lymphoma.Results and conclusions of the European Intergroup EURO-LB02 trial in children and adolescents with lymphoblastic lymphoma.Complex MLL rearrangement in non-infiltrated bone marrow in an infant with stage II precursor B-lymphoblastic lymphoma.Proposal of a genetic classifier for risk group stratification in pediatric T-cell lymphoblastic lymphoma reveals differences from adult T-cell lymphoblastic leukemia.Neurotoxic side effects in children with refractory or relapsed T-cell malignancies treated with nelarabine based therapy.Risk factors predicting the survival of pediatric patients with relapsed/refractory non-Hodgkin lymphoma who underwent hematopoietic stem cell transplantation: a retrospective study from the Turkish pediatric bone marrow transplantation registry.Nelarabine toxicity in children and adolescents with relapsed/refractory T-ALL/T-LBL: can we avoid throwing the baby out with the bathwater?European Society for Blood and Marrow Transplantation Analysis of Treosulfan Conditioning Before Hematopoietic Stem Cell Transplantation in Children and Adolescents With Hematological Malignancies.Treatment outcome in T-cell lymphoblastic lymphoma in adults - a population-based study from the Swedish Lymphoma Registry.Immunotherapy with the trifunctional anti-CD20 × anti-CD3 antibody FBTA05 in a patient with relapsed t(8;14)-positive post-transplant lymphoproliferative disease.Clinical presentation, evolution, and prognosis of precursor B-cell lymphoblastic lymphoma in trials LMT96, EORTC 58881, and EORTC 58951.
P2860
Q26746934-0D1CA4E1-BBFD-44C0-9FF0-A0809864D306Q26797513-BA0479E5-1BE4-4B85-9C65-616DA333366BQ33559438-F779B843-DC53-4736-B8A7-1DC831B109C5Q33770560-DA743156-CAE7-4180-96E0-7FE662A12315Q34645259-587A1D2A-A1EA-4E52-ABB8-EF0B202199C4Q34773043-C3C2A91D-5FFC-46D1-B97D-2CFA92BBB977Q35159889-C1A13F07-E1B4-4733-8121-1500D949FA29Q36995625-FAE0DCFB-3F5E-418D-89DD-FC500B90E470Q38102065-DFB5C378-96E2-406F-8CF0-8CFD8253A24DQ38112088-70E4A981-9EFD-42E1-B814-9E8FD3D46F17Q38115231-24F78AC1-8A99-48EF-AC69-E3724453FF53Q38138608-73AC0D1A-D9D0-4224-92EB-BD8B48532247Q38371659-4503CF35-E5CD-4A4C-834B-6CDAAD52AB23Q38387292-BCBB8DBC-A8AD-4A9E-8DE8-033486DF801DQ38576104-33390F8D-5E66-4108-8495-28B0EE0EA6D4Q38644266-52FC7BDA-DF75-4A36-B72A-965B783AD654Q38672607-D3042E85-BB71-4007-A683-D96E873B9558Q38771110-4E6D9A76-8AD6-497C-987E-F4CA0F69D0D3Q38779952-326599DC-C174-42CB-8699-1CB2DF10CE0DQ38822525-0F88349C-D460-4578-AAA0-902E11479FB9Q39578363-F6775A70-44BD-4BFF-9C50-54859B57765DQ39869982-53C03319-9D61-46B3-967A-EA2AFA741BF9Q40799494-AE4967F3-5585-475C-8E8C-50369ABACCB1Q40836510-AF3047BF-AA43-469A-BFE2-FE8BBB856248Q41942675-3A45CEB0-48CD-467E-80C0-1F4A744F3189Q42585846-1C5CBD68-BE9A-487B-8D65-91B15BB52148Q43738084-205EA84C-24E8-40A3-88CD-7B0BAE6E3DBFQ43891574-203952D1-4B2E-43D0-B7BB-F5683312EFB3Q44585347-C9D2803B-2CA6-4C5A-8F32-1875990F51F9Q45309842-5BA7FC03-BEB0-483A-A609-1C1574E92FCEQ47103786-184774F0-7DC1-4890-ADEB-9D6F9DB7C088Q47789188-CBCBAD54-C044-46BE-9EB3-382BCC51D2B0Q48153742-93DCA799-8555-42A7-912F-7732F163EE60Q48298283-51490DC3-DC5C-43E4-A98B-0B9D8629E2D4Q48341313-D8FD1440-7D93-49C6-A5A8-3DA01CBD0CF1Q50168849-E3B285BF-A562-40AC-B94A-9C5B154055FAQ50854536-6024EAEF-9965-47C6-85A4-143ADF20647AQ51075724-60786DAA-BF05-40A5-8CD8-4EEE367713D4Q52842514-DC364FC6-AD1D-4688-901D-91DA0D174EE7Q52899418-6A66ABFB-FFF8-4C04-B888-4E8A9EE8426F
P2860
Poor outcome for children and adolescents with progressive disease or relapse of lymphoblastic lymphoma: a report from the berlin-frankfurt-muenster group.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Poor outcome for children and ...... rlin-frankfurt-muenster group.
@en
Poor outcome for children and ...... rlin-frankfurt-muenster group.
@nl
type
label
Poor outcome for children and ...... rlin-frankfurt-muenster group.
@en
Poor outcome for children and ...... rlin-frankfurt-muenster group.
@nl
prefLabel
Poor outcome for children and ...... rlin-frankfurt-muenster group.
@en
Poor outcome for children and ...... rlin-frankfurt-muenster group.
@nl
P2093
P356
P1476
Poor outcome for children and ...... rlin-frankfurt-muenster group.
@en
P2093
Alfred Reiter
Birgit Burkhardt
Eva Landmann
Günter Henze
Lisa Lassay
Max Lakomek
Peter Lang
Roswitha Dickerhoff
P304
P356
10.1200/JCO.2008.19.3367
P407
P577
2009-05-11T00:00:00Z